Our goals were to profile the sensitivity of cancer cells to the HDAC inhibitors trichostatin A and depsipeptide, to compare their relative potency and specificity across panels of lung cancer, breast cancer and melanoma cell lines, and to define phenotypes unique to each inhibitor. The gene discussed is HDAC9; the disease is breast carcinoma.